

Issue Date: [January 18th, 2016]

Call for Grant Notification: Genentech Medical Education & Research Grants

The *Medical Education & Research Grants Team at Genentech, a member of the Roche Group*, invites members of the research community to submit applications for innovative research grants subject to the terms described below. This Call for Grants Notification (CGN) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific needs exist and funding is available.

Purpose: As part of our scientific mission, Genentech provides grants for scientific projects and fellowship programs that are aligned with our mission to (1) foster advances in scientific research and discovery; and (2) support advanced study by clinical and research professionals at accredited universities or training institutions. Genentech CGNs are posted on the Genentech website (<http://funding.gene.com>) along with the several social media outlets. In addition, an email is sent out to all registered users of the Genentech Financial Request System (gFRS) who have previously submitted an application for support of an independent education activity.

Eligibility Criteria: Applicant must be registered on the Genentech Financial Request System (gFRS).

Geographical Scope: The research activity must be U.S.-based only unless specifically identified as a *Global Grant*.

Submission Instructions:

1. Researchers who meet the eligibility criteria and are interested in submitting a response to this CGN submit applications online through gFRS, which can be accessed via <http://funding.gene.com>. When submitting the application, please be sure the following are completed:
 - a. Select the *Therapeutic Area*, and the *Disease State* for the grant(s) that you are submitting.
 - b. Include “CGN_IPF_2016” [Insert Program Title] in the program title of the grant application
 - c. Complete all sections of online grant request form
 - d. Upload all documentation as requested by the system
 - e. **Deadline for Submission of Application(s): [Friday, March 11th, 2016] (11:59 PM Pacific Time)**

Award Decision Date/Mechanism: Approvals and denials will be communicated via standard grant-submission means (email notifications) no later than [April 30th, 2016]. *There have been no pre-determined approvals, nor any identified preferred researchers or research institutions. All submissions will be reviewed equally and thoroughly.*

Researchers should not respond to this CGN unless they have read and understand the terms, purpose, therapeutic landscape, and research request identified below. Applicants will be expected to identify independent gaps that are scientifically accurate and relevantly aligned to these CGNs.

Therapeutic Area and Disease Area	[Idiopathic Pulmonary Fibrosis Research. (2 research projects budget approximately \$100,000)]
Background	Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease of unknown etiology that occurs primarily in older adults and is defined by clinicopathologic criteria, including the histologic and/or radiologic pattern of usual interstitial pneumonia (1). The median survival of patients with IPF is approximately 3 years from the time of diagnosis (2). To date, many aspects-IPF remain unknown and require further study. These include among others the potential to diagnose the disease earlier, to further our understanding of disease progression and underlying causes of IPF (3).
Methods	Genentech is seeking to support 2 research projects that are designed to improve our understanding of IPF. The proposed research can be focused on any one of a number of basic, translational or clinical research topics that will improve our understanding of the onset, progression, or treatment of IPF.
Measures and Results	The successful research project will incorporate a groundbreaking exploration of idiopathic pulmonary fibrosis. Potential applicants are encouraged to describe how their proposed research-if successful-may impact our understanding of IPF and,

ultimately, result in more effective treatment of patients with IPF.

Discussion

- Standard statement in each CGN:** Researchers who are awarded approval agree to:
1. Demonstrate key findings via outcomes analysis (please see Measures and Results section immediately above)
 2. Summarize (through written analysis) the researcher's understanding of the metrics, identifying the association between the research and the outcomes, identifying any comparison of the results with findings from other identified publications (if relevant)
 3. Identify any unanticipated *barriers* and *research limitations* explaining the reasons for them, and describing the efforts that were/are being made to adjust them as necessary
 4. Be available for discussion and/or presentation if requested by Genentech's respective Medical Education Manager

**Genentech is also committed to providing non-solicited grant support in all disease areas.*

Additional Considerations

All grant submissions should describe how the proposed research plans to determine the extent to which the initiatives have met the stated objectives and closed the clinical gap(s).

While not required, it is strongly recommended that the results of these research initiatives aim to increase understanding around the elements identified within the chart within this CGN. Genentech will review ways the aforementioned information ties into the following components:

- Research that results in an improvement of quality metrics, quality of care, and/or quality of life
- Research that results in a way to sustainably improve population health for a community
- Additionally, a plan for publishing the results detailing the lessons learned would be welcomed

Genentech's Grant Decision-Making Criteria

Please refer to the publicly available criteria, which can be found at <http://funding.gene.com>.

Terms and Conditions

1. All grant applications received in response to this CGN will be reviewed in accordance with all Genentech policies and policy guidelines.
2. This CGN does not commit Genentech to award a grant or to pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this CGN.
4. For compliance reason, and in fairness to all grantees, all communications about this CGN must come exclusively to Genentech's department for Medical Education & Research Grants. Failure to comply will automatically disqualify grantees.
5. Failure to follow instruction within this CGN may result in a denial.

Transparency

Genentech, at its sole discretion, has the right to disclose the details of funded independent research projects, including those that may be required by federal, state, and/or local laws and regulations. This disclosure may include, but shall not be limited to, details of the activity and the grant amount. The information may be disclosed to the public in a manner including, but not limited to, disclosure on the Genentech website.

References

1. Raghu, Ganesh, et al. "An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline." *American journal of respiratory and critical care medicine* 192.2 (2015): e3-e19.
2. Raghu, Ganesh, et al. "Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11." *The Lancet Respiratory Medicine* 2.7 (2014): 566-572.
3. Meyer, Keith C., et al. "Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient: Addressing Key Questions." *CHEST Journal* 148.1 (2015): 242-252